MyoKardia Inc. plans to use its scientific founders' insights about the genetic underpinnings of cardiomyopathies to discover and develop small molecules to treat subsets of the heart disease. It hopes to achieve preclinical proof-of-concept within 24-36 months.

The company represents the convergence of work in muscle biology and cardiovascular genetics that recently have emerged from Harvard Medical School, Stanford University and the University of Colorado.